Author: claimsbot

1. An adhesive retainer for fixing to a structure with at least one adhesive foot which has a supporting base region formed on the adhesive foot and is provided with receiving openings which extend like capillaries through the supporting base region into the interior of the adhesive foot.
2. The adhesive retainer according to claim 1, wherein the receiving openings are configured to form an integral bond with the structure, such that when the adhesive foot is placed on the structure, which is covered for this purpose with a liquid, solidifiable bonding substance, the receiving openings receive bonding substance due to capillary ascension.
3. The adhesive retainer according to claim 2, wherein the receiving openings are configured to receive lacquer andor paint andor adhesive andor synthetic resin as the liquid bonding substance.
4. The adhesive retainer according to claim 1, wherein the supporting base region is substantially planar.
5. The adhesive retainer according to claim 1, wherein the receiving openings extend substantially vertically from the supporting base region into the interior of the adhesive foot.
6. The adhesive retainer according to claim 1, wherein the adhesive retainer comprises plastics material.
7. The adhesive retainer according to claim 1, wherein the adhesive retainer is formed in one piece.
8. The adhesive retainer according to claim 1, wherein the supporting base region of the at least one adhesive foot is formed with three or more projecting spacer pins.
9. The adhesive retainer according to claim 1, wherein the supporting base region of the at least one adhesive foot is formed with at least one projecting fixing pin.
10. The adhesive retainer according to claim 1, wherein two adhesive feet are formed which can be coupled together by a connection element.
11. The adhesive retainer according to claim 1, wherein at least some of the receiving openings extend through the at least one adhesive foot.
12. The adhesive retainer according to claim 1, furthermore with a retaining device which is attached to the at least one adhesive foot and is configured to join the adhesive retainer to a component.
13. The adhesive retainer according to claim 12, wherein the retaining device is attached to a side of the adhesive foot opposite the supporting base region.
14. A method for fixing an adhesive retainer to a structure, comprising:
placing a supporting base region of an adhesive foot of an adhesive retainer on the structure covered with a liquid, solidifiable bonding substance;
wetting the supporting base region of the adhesive foot with the liquid bonding substance and receiving the liquid bonding substance in receiving openings extending like capillaries through the supporting base region into the interior of the adhesive foot; and
solidifying the liquid bonding substance at least in the region of the applied adhesive foot.
15. The method according to claim 14, wherein the liquid, solidifiable bonding substance comprises lacquer andor paint andor adhesive andor synthetic resin.
16. The method according to claim 15, wherein the liquid, solidifiable bonding substance is a synthetic resin and the solidification step comprises curing using an autoclave.
17. The method according to claim 16, further comprising fixing the adhesive foot on the structure by at least one fixing needle.
18. The method according to claim 16, further comprising covering the structure with a film and evacuating the covered structure through at least some of the receiving openings in the adhesive foot.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A calibration system comprising, in combination:
a non-contact tonometer operable to measure intraocular pressure of an eye by discharging an air pulse at the eye to applanate a cornea of the eye, the non-contact tonometer including a nosepiece including a fluid discharge passage for discharging the air pulse along a test axis at the cornea, wherein the nosepiece is movable relative to the cornea to align the test axis with the cornea; and
a tonometer calibration tool removably mounted on the nosepiece, the calibration tool including (i) a pressure sensor arranged to receive the air pulse to provide a pressure signal in response to the air pulse and (ii) a radiation emitter, wherein the radiation emitter provides a pseudo-applanation event when the pressure signal reaches a predetermined level, the pseudo-applanation event being detectable by the non-contact tonometer as though an actual corneal applanation had taken place;
wherein the tonometer calibration tool further includes a mounting orifice receiving a portion of the nosepiece to removably mount the tonometer calibration tool on the nosepiece.
2. The calibration system according to claim 1, wherein the pressure sensor is arranged in alignment with test axis.
3. The calibration system according to claim 2, wherein the calibration tool includes a noise reduction surface separating the pressure sensor from the mounting orifice, the noise reduction surface having a plurality of ridges extending in a direction non-parallel to the test axis.
4. The calibration system according to claim 3, wherein the calibration tool is open across the noise reduction surface.

1. An ultrasound imaging system comprising:
a memory configured to store a single copy of beam forming parameters for each beam that can be created by the ultrasound system, and
a hierarchy of sequencers including a frame sequencer configured to store parameters for a number of lines for a frame of ultrasound data to be created and an address sequencer configured to compute an address in the memory where beam forming parameters for a current line of the frame can be retrieved, wherein the frame sequencer is configured to provide parameters for a current line in the frame to the address sequencer and wherein the address sequencer is configured to compute an address in the memory for retrieving the beam forming parameters for each line in the frame on a line by line basis based on the parameters received from the frame sequencer.
2. The system of claim 1, wherein said memory stores information that includes information other than been forming parameters.
3. The system of claim 2, wherein said information stored in said memory comprises pointer information identifying where the beam forming parameters which are used in creating the beams are stored.
4. The system of claim 1, wherein said frame sequencer is initialized for use in different imaging modes by providing parameters thereto.
5. The system of claim 1, wherein said address is determined as an offset from a base address in at least one dimension of an array in said memory.
6. The system of claim 1, wherein said hierarchy of sequencers are implemented in one or more application specific circuits.
7. The system of claim 1, wherein said ultrasound imaging system comprises a portable diagnostic ultrasound instrument.
8. The system of claim 1, wherein said memory stores the beam forming parameters in at least a three dimensional array.
9. The ultrasound system of claim 1, wherein the address sequencer is configured to compute the address for the beam forming parameters for the current line based on offsets to a base address that are associated with an imaging mode, an imaging zone and a current line in the frame of ultrasound data to be created.
10. The ultrasound system of claim 9, further comprising front end circuitry, configured to access the memory and wherein the base address is a register address space of the front end circuitry.
11. A method performed by a processor of an ultrasound system to access beam forming parameters to be used in ultrasound imaging system beam forming, said method comprising:
sending parameters for a current line to be created in a frame of ultrasound data from a frame sequencer to an address sequencer, wherein the parameters are indicative of a zone to be imaged and an imaging mode for the current line, and
computing an address in the address sequencer from which beam forming parameters are to be retrieved from a memory that stores a single copy of the beam forming parameters for each beam that can be created by the ultrasound system, wherein the address sequencer computes an address of the beam forming parameters for a current line on a line-by-line basis based on one or more of the parameters received from the frame sequencer; and
retrieving the beam forming parameters for the current line from the computed address.
12. The method of claim 11, wherein said memory is configured as a multi-dimensional array that stores beam forming parameters at locations that can be accessed based on at least an image mode and an image zone.
13. The method of claim 12, further comprising retrieving information from said multi-dimensional array that comprises information other than beam forming parameters.
14. The method of claim 12, further comprising retrieving pointer information from the multi-dimensional array that identifies where the beam forming parameters for a line are stored.
15. The method of claim 12, wherein said multi-dimensional array comprises at least a three dimensional array.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An implantable device, comprising a coating deposited thereon that comprises a polymer derived from lactide (LA), glycolide (GA), and poly(ethylene glycol) (PEG),
wherein the LA is D,L-lactide (DLLA), L-lactide (LLA), D-lactide (DLA), meso-lactide (mLA) or combinations thereof,
wherein the polymer has a weight average molecular weight (Mw) from about 50 KD to about 200 KD and comprises:
a content of GA from about 10% to about 50% by weight; and
a content of PEG from about 5% to about 50% by weight, and

wherein the coating is capable of fully absorbed within 12 months upon exposure to a physiological environment.
2. The implantable device of claim 1, wherein the polymer has a molecular weight of about 100 KD or above.
3. The implantable device of claim 1, wherein the polymer comprises a block selected from poly(DLLA-co-GA), poly(LLA-co-GA), poly(DLA-co-GA), or poly(mLA-co-GA).
4. The implantable device of claim 3, wherein the block has a LAGA ratio from about 991 to about 199.
5. The implantable device of claim 3, wherein the block has a LAGA ratio from about 9010 to about 1090.
6. The implantable device of claim 3, wherein the block has a LAGA ratio from about 7030 to about 3070.
7. The implantable device of claim 1, wherein the content of PEG is about 20-80% by weight.
8. The implantable device of claim 1, wherein the content of PEG is about 30% or about 40% by weight.
9. The implantable device of claim 1, wherein the polymer breaks into fragments upon exposure of the coating to a physiological environment.
10. The implantable device of claim 1, wherein the coating further comprises a bioactive agent.
11. The implantable device of claim 10, wherein the bioactive agent is selected from paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-2-(2-hydroxy)ethoxyethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), \u03b3-hiridun, clobetasol, pimecrolimus, imatinib mesylate, midostaurin, feno fibrate, prodrugs thereof, co-drugs thereof, and combinations thereof.
12. The implantable device of claim 1, which is a stent.
13. The implantable device of claim 1, which is a bioabsorbable stent.
14. A method, comprising depositing a coating over the implantable device, the coating comprising a polymer derived from lactide (LA), glycolide (GA), and poly(ethylene glycol) (PEG),
wherein the LA is D,L-lactide (DLLA), L-lactide (LLA), D-lactide (DLA), meso-lactide (mLA) or combinations thereof,
wherein the polymer has a weight average molecular weight (Mw) from about 50 KD to about 200 KD and comprises:
a content of GA from about 10% to about 50% by weight; and
a content of PEG from about 5% to about 50% by weight, and

wherein the coating is capable of fully absorbed within 12 months upon exposure to a physiological environment.
15. The method of claim 14, wherein the polymer has a molecular weight of about 50 KD or above.
16. The method of claim 14, wherein the polymer comprises a block selected from poly(DLLA-co-GA), poly(LLA-co-GA), poly(DLA-co-GA), or poly(mLA-co-GA).
17. The method of claim 16, wherein the block has a LAGA ratio from about 991 to about 199.
18. The method of claim 16, wherein the block has a LAGA ratio from about 9010 to about 1090.
19. The method of claim 16, wherein the block has a LAGA ratio from about 7030 to about 3070.
20. The method of claim 14, wherein the content of PEG is about 20-80% by weight.
21. The method of claim 14, wherein the content of PEG is about 30% or about 40% by weight.
22. The method of claim 14, wherein the polymer breaks into fragments upon exposure of the coating to a physiological environment.
23. The method of claim 14, wherein the polymeric matrix further comprises a bioactive agent.
24. The method of claim 23, wherein the bioactive agent is selected from paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-2-(2-hydroxy)ethoxyethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), \u03b3-hiridun, clobetasol, pimecrolimus, imatinib mesylate, midostaurin, feno fibrate, prodrugs thereof, co-drugs thereof, and combinations thereof.
25. A method, comprising implanting in a patient an implantable device according to claim 1, wherein the disorder is selected from the group consisting of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.